Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1985 Jun;82(12):4258–4262. doi: 10.1073/pnas.82.12.4258

Coronary thrombolysis with facilitated absorption of intramuscularly injected tissue-type plasminogen activator.

B E Sobel, L E Fields, A K Robison, K A Fox, S J Sarnoff
PMCID: PMC397976  PMID: 3858878

Abstract

Conventional activators of the fibrinolytic system used for coronary thrombolysis entail unavoidable delay, risk of bleeding, or both in contrast to tissue-type plasminogen activator (t-PA). Because the potential benefit of coronary thrombolysis is inversely related to the duration of antecedent ischemia, this study was performed to develop an approach for facilitated absorption of intramuscularly injected t-PA potentially adaptable for prompt, self-medication. In rabbits, absorption was markedly potentiated by hydroxylamine hydrochloride and electrical stimulation at the injection site. Intramuscular administration of t-PA in doses of 1 mg/kg of body weight, comparable to amounts given intravenously to patients (0.5-0.75 mg/kg), elicited peak blood levels of 431 +/- 52 (SEM) ng/ml 5 min after injection, well within the therapeutic range. In dogs, absorption facilitated by hydroxylamine promptly elicited angiographically documented coronary thrombolysis as well. The approach developed should ultimately permit prompt coronary thrombolysis and enhanced salvage of jeopardized ischemic myocardium in patients with life-threatening coronary thrombi.

Full text

PDF
4258

Images in this article

4261Image
on p.4261

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson J. L., Marshall H. W., Bray B. E., Lutz J. R., Frederick P. R., Yanowitz F. G., Datz F. L., Klausner S. C., Hagan A. D. A randomized trial of intracoronary streptokinase in the treatment of acute myocardial infarction. N Engl J Med. 1983 Jun 2;308(22):1312–1318. doi: 10.1056/NEJM198306023082202. [DOI] [PubMed] [Google Scholar]
  2. Bergmann S. R., Fox K. A., Ter-Pogossian M. M., Sobel B. E., Collen D. Clot-selective coronary thrombolysis with tissue-type plasminogen activator. Science. 1983 Jun 10;220(4602):1181–1183. doi: 10.1126/science.6602378. [DOI] [PubMed] [Google Scholar]
  3. Bergmann S. R., Lerch R. A., Fox K. A., Ludbrook P. A., Welch M. J., Ter-Pogossian M. M., Sobel B. E. Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. Am J Med. 1982 Oct;73(4):573–581. doi: 10.1016/0002-9343(82)90338-2. [DOI] [PubMed] [Google Scholar]
  4. Brommer E. J. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis; inefficiency of activators added afterwards. Thromb Res. 1984 Apr 15;34(2):109–115. doi: 10.1016/0049-3848(84)90067-7. [DOI] [PubMed] [Google Scholar]
  5. Collen D., Topol E. J., Tiefenbrunn A. J., Gold H. K., Weisfeldt M. L., Sobel B. E., Leinbach R. C., Brinker J. A., Ludbrook P. A., Yasuda I. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation. 1984 Dec;70(6):1012–1017. doi: 10.1161/01.cir.70.6.1012. [DOI] [PubMed] [Google Scholar]
  6. Cowley M. J., Hastillo A., Vetrovec G. W., Hess M. L. Effects of intracoronary streptokinase in acute myocardial infarction. Am Heart J. 1981 Dec;102(6 Pt 2):1149–1158. doi: 10.1016/0002-8703(81)90646-3. [DOI] [PubMed] [Google Scholar]
  7. DeWood M. A., Spores J., Notske R., Mouser L. T., Burroughs R., Golden M. S., Lang H. T. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980 Oct 16;303(16):897–902. doi: 10.1056/NEJM198010163031601. [DOI] [PubMed] [Google Scholar]
  8. Diamond J. Lack of correlation between cyclic GMP elevation and relaxation of nonvascular smooth muscle by nitroglycerin, nitroprusside, hydroxylamine and sodium azide. J Pharmacol Exp Ther. 1983 May;225(2):422–426. [PubMed] [Google Scholar]
  9. Iizuka K., Kikugawa K. Platelet aggregation inhibitors. I. Hydroxylamine: a potent inhibitor of platelet aggregation. Chem Pharm Bull (Tokyo) 1972 Mar;20(3):614–616. doi: 10.1248/cpb.20.614. [DOI] [PubMed] [Google Scholar]
  10. JACOB S. W., BISCHEL M., HERSCHLER R. J. DIMETHYL SULFOXIDE: EFFECTS ON THE PERMEABILITY OF BIOLOGIC MEMBRANES (PRELIMINARY REPORT). Curr Ther Res Clin Exp. 1964 Mar;6:193–198. [PubMed] [Google Scholar]
  11. Kennedy J. W., Ritchie J. L., Davis K. B., Fritz J. K. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med. 1983 Dec 15;309(24):1477–1482. doi: 10.1056/NEJM198312153092402. [DOI] [PubMed] [Google Scholar]
  12. Klein M. S., Shell W. E., Sobel B. E. Serum creatine phosphokinase (CPK ) isoenzymes after intramuscular injections, surgery, and myocardial infarction. Experimental and clinical studies. Cardiovasc Res. 1973 May;7(3):412–418. doi: 10.1093/cvr/7.3.412. [DOI] [PubMed] [Google Scholar]
  13. Layne W. R., Smith R. P. Methylene blue uptake and the reversal of chemically induced methemoglobinemias in human erythrocytes. J Pharmacol Exp Ther. 1969 Jan;165(1):36–44. [PubMed] [Google Scholar]
  14. Levin E. G. Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci U S A. 1983 Nov;80(22):6804–6808. doi: 10.1073/pnas.80.22.6804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lockey S. D. A new method of administering aqueous epinephrine: the EpiPen, an automatic syringe. J Asthma Res. 1980 Jul;17(4):153–155. doi: 10.3109/02770908009105665. [DOI] [PubMed] [Google Scholar]
  16. Martin T. R., Kastor J. A., Kershbaum K. L., Engelman K. The effects of atropine administered with standard syringe and a self-injector device. Am Heart J. 1980 Mar;99(3):282–288. doi: 10.1016/0002-8703(80)90341-5. [DOI] [PubMed] [Google Scholar]
  17. Merx W., Dörr R., Rentrop P., Blanke H., Karsch K. R., Mathey D. G., Kremer P., Rutsch W., Schmutzler H. Evaluation of the effectiveness of intracoronary streptokinase infusion in acute myocardial infarction: postprocedure management and hospital course in 204 patients. Am Heart J. 1981 Dec;102(6 Pt 2):1181–1187. doi: 10.1016/0002-8703(81)90650-5. [DOI] [PubMed] [Google Scholar]
  18. Patterson R., Valentine M. Anaphylaxis and related allergic emergencies including reactions due to insect stings. JAMA. 1982 Nov 26;248(20):2632–2636. [PubMed] [Google Scholar]
  19. REMENSNYDER J. P., MITCHELL J. H., SARNOFF S. J. Functional sympatholysis during muscular activity. Observations on influence of carotid sinus on oxygen uptake. Circ Res. 1962 Sep;11:370–380. doi: 10.1161/01.res.11.3.370. [DOI] [PubMed] [Google Scholar]
  20. Reduto L. A., Freund G. C., Gaeta J. M., Smalling R. W., Lewis B., Gould K. L. Coronary artery reperfusion in acute myocardial infarction: beneficial effects of intracoronary streptokinase on left ventricular salvage and performance. Am Heart J. 1981 Dec;102(6 Pt 2):1168–1177. doi: 10.1016/0002-8703(81)90648-7. [DOI] [PubMed] [Google Scholar]
  21. Rentrop K. P., Feit F., Blanke H., Stecy P., Schneider R., Rey M., Horowitz S., Goldman M., Karsch K., Meilman H. Effects of intracoronary streptokinase and intracoronary nitroglycerin infusion on coronary angiographic patterns and mortality in patients with acute myocardial infarction. N Engl J Med. 1984 Dec 6;311(23):1457–1463. doi: 10.1056/NEJM198412063112301. [DOI] [PubMed] [Google Scholar]
  22. Rentrop P., Blanke H., Karsch K. R., Kaiser H., Köstering H., Leitz K. Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris. Circulation. 1981 Feb;63(2):307–317. doi: 10.1161/01.cir.63.2.307. [DOI] [PubMed] [Google Scholar]
  23. Schröder R., Biamino G., von Leitner E. R., Linderer T., Brüggemann T., Heitz J., Vöhringer H. F., Wegscheider K. Intravenous short-term infusion of streptokinase in acute myocardial infarction. Circulation. 1983 Mar;67(3):536–548. doi: 10.1161/01.cir.67.3.536. [DOI] [PubMed] [Google Scholar]
  24. Sheridan D. J., Penkoske P. A., Sobel B. E., Corr P. B. Alpha adrenergic contributions to dysrhythmia during myocardial ischemia and reperfusion in cats. J Clin Invest. 1980 Jan;65(1):161–171. doi: 10.1172/JCI109647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Smith R. P., Olson M. V. Drug-induced methemoglobinemia. Semin Hematol. 1973 Jul;10(3):253–268. [PubMed] [Google Scholar]
  26. Sobel B. E., Geltman E. M., Tiefenbrunn A. J., Jaffe A. S., Spadaro J. J., Jr, Ter-Pogossian M. M., Collen D., Ludbrook P. A. Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinase. Circulation. 1984 May;69(5):983–990. doi: 10.1161/01.cir.69.5.983. [DOI] [PubMed] [Google Scholar]
  27. Tennant S. N., Dixon J., Venable T. C., Page H. L., Jr, Roach A., Kaiser A. B., Frederiksen R., Tacogue L., Kaplan P., Babu N. S. Intracoronary thrombolysis in patients with acute myocardial infarction: comparison of the efficacy of urokinase with streptokinase. Circulation. 1984 Apr;69(4):756–760. doi: 10.1161/01.cir.69.4.756. [DOI] [PubMed] [Google Scholar]
  28. Tiefenbrunn A. J., Robinson A. K., Kurnik P. B., Ludbrook P. A., Sobel B. E. Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology. Circulation. 1985 Jan;71(1):110–116. doi: 10.1161/01.cir.71.1.110. [DOI] [PubMed] [Google Scholar]
  29. Tran-Thang C., Kruithof E. K., Bachmann F. The mechanism of in vitro clot lysis induced by vascular plasminogen activator. Blood. 1984 Jun;63(6):1331–1337. [PubMed] [Google Scholar]
  30. Valentine P. A., Frew J. L., Mashford M. L., Sloman J. G. Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study. N Engl J Med. 1974 Dec 19;291(25):1327–1331. doi: 10.1056/NEJM197412192912505. [DOI] [PubMed] [Google Scholar]
  31. Van de Werf F., Bergmann S. R., Fox K. A., de Geest H., Hoyng C. F., Sobel B. E., Collen D. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. Circulation. 1984 Mar;69(3):605–610. doi: 10.1161/01.cir.69.3.605. [DOI] [PubMed] [Google Scholar]
  32. Van de Werf F., Ludbrook P. A., Bergmann S. R., Tiefenbrunn A. J., Fox K. A., de Geest H., Verstraete M., Collen D., Sobel B. E. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med. 1984 Mar 8;310(10):609–613. doi: 10.1056/NEJM198403083101001. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES